Jefferies analysts expect a regulatory filing for rocatinlimab later this year, with a product launch in 2026.

Amgen and Kyowa Kirin announced preliminary top-line results from the ASCEND study, evaluating the investigational therapy ...

Kura Oncology, Inc. ( NASDAQ: KURA) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 1:50 PM EDT ...

On September 9, Seema Shah, Chief Global Strategist at Principal Asset Management, appeared on CNBC for an interview to ...

Two head-to-head phase III trials demonstrated superior efficacy, including overall survival versus a daratumumab-based ...

Physicians significantly underestimated the proportion of patients with systemic sclerosis who experienced pain, with rates of 43.4% vs 96.0%.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Elevate Your Investing Strategy: Take advantage of ...